The stock market celebrates Genfit's Phase II results
Shares of the French diabetes specialist almost doubled when the company
published results of its Phase II study with the PPAR alpha and delta
modulator GFT505. The compound has met the co-primary and secondary
endpoints while showing no adverse side-effects. It helped to improve
insulin sensitivity in the liver and peripheral tissues. It is intended to
treat non-alcoholic fatty liver disease (NAFLD)/non-alcoholic
steatohepatitis (NASH). The product significantly reduced insulin-induced
hepatic glucose production by 0.86 mg/kg/min from baseline to week 8 vs.
0.63 mg/kg/min for placebo (p=0.006). The single blinded trial in French
centres enrolled 22 insulin-resistant patients with abdominal obesity.
GFT505 is the most advanced compound of a group of drug candidates developed by Genfit. It targets multiple risk factors of pre-diabetes and diabetes: hyperglycaemia and insulin resistance, atherogenic dyslipidemia and
inflammation, as well as certain liver disorders often associated with
pre-diabetic and diabetic states. Genfit was founded in 1999 Loos/France.
The company employs about 100 people and is listed at Alternext on the NYSE
Euronext Stock Exchange. The biotech still owns global rights to all of its